The Division of Pediatric Infectious Diseases has a golden history at Emory.

1964 - 2002     During Dr. Andre Nahmias' leadership, the Division of Pediatric Infectious Diseases grew and excelled in clinical services, research productivity, teaching and child advocacy.

2002 - 2005     Dr. Harry L. Keyserling was Interim Director of the Division of Infectious Diseases, Epidemiology, and Immunology from 2002-2005.  He is currently a Professor Emeritus, having retired in 2013.  He joined the faculty at Emory University in 1982.  Dr. Keyserling’s interests centered around virology, hospital epidemiology, and clinical vaccinology.   During his thirty years at Emory, he conducted over 100 clinical vaccine trials in children and adults

2005 - 2016     Dr. Paul Spearman served as Director of Pediatric Infectious Diseases from 2005-2016.  During his tenure at Emory University School of Medicine, he was appointed the Vice Chair for Research for the Department of Pediatrics and Chief Research Officer for Children’s Healthcare of Atlanta.  Dr. Spearman left Emory in September 2016 to become Director of the Division of Pediatric Infectious Diseases at Cincinnati Children’s Hospital in Cincinnati, OH.

2016 - present  Dr. Andi Shane became the Interim Director of the Pediatric Infectious Diseases Division at Emory in September of 2016.  Dr. Shane came to Emory in 2006 from a Pediatric Infectious Diseases Fellowship in San Francisco, CA.  

Over 50 fellows in Pediatric Infectious Disease and 20 post-doctoral Ph.D. fellows have trained with us. Faculty members have participated as visiting professors, speakers or chairs in over 200 institutions in the US and more than 100 abroad. They have contributed over 300 peer-reviewed journal publications, more than 90 book chapters and authored 4 books. Division members have had continuous federal grant support, institutional grants, eleven CDC grants and one U.S. Army grant. Non-governmental funding includes: March of Dimes, American Cancer Society, Stanley Foundation, and the Macy Foundation. More than sixty clinical trials have been supported by pharmaceutical companies. 
We look forward, as always, to seeing the next chapter unfold.